Community Home Health & Hospice

chhh.org

Community Home Health & Hospice (Community) is a local independent nonprofit healthcare agency. Community has served the healthcare needs of Washington and Oregon families since 1977. Every day, we deliver care to 600 people where they live through home care personal services, home health, hospice and bereavement services in the following four counties: Clark, Cowlitz, and Wahkiakum in Washington and Columbia in Oregon. We foster clinical excellence for which we have received recognition annually since 2008 as a HomeCare Elite top agency. Community supports the healthcare and independent living goals of each patient and their loved ones by delivering the highest quality, compassionate and dignified care to individuals in their chosen place of residence.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research, PHARMA TECH

POSITIVE RESULTS FOR AMBRX’S PROPRIETARY ANTI-PSMA ADC, ARX517, IN PROSTATE CANCER

Ambrx | February 21, 2023

news image

Ambrx Biopharma Inc., recently released positive preliminary results from its current Phase 1 trial, APEX-01 (NCT04662580), which is examining ARX517, Ambrx's patented anti-PSMA ADC, in patients with prostate cancer. Patients with advanced prostate cancer who have progressed on at least two prior FDA-approved treatments are enrolled in the Phase 1, first-in-human, open label dose escalation and dose expansion experiment known as APEX-01. In the US, APEX-01 is the only clinic...

Read More

Pharma Tech

XERIS PHARMACEUTICALS ENTERS COLLABORATION AGREEMENT WITH MERCK

Xeris | October 25, 2021

news image

Xeris Biopharma Holdingsa biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck , with an option to license Xeris “We are quite excited to be working closely with Merck on this opportunity using our novel platform technology, XeriJect The XeriJect platform has broad applicability in improving the delivery of...

Read More

Business Insights

CYCLENIUM PHARMA AND VUJA DE SCIENCES ANNOUNCE ONCOLOGY DRUG DISCOVERY COLLABORATION

Cyclenium Pharma | January 06, 2022

news image

Cyclenium Pharma, Inc. an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, and Vuja De Sciences, Inc. a biotechnology startup dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence, have announced today the signing of a drug discovery collaboration agreement. The companies will ...

Read More

Business Insights

ACURX PHARMACEUTICALS TO JOIN THE RUSSELL MICROCAP INDEX®

Acurx Pharmaceuticals, Inc. | September 06, 2021

news image

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate gr...

Read More
news image

Research, PHARMA TECH

POSITIVE RESULTS FOR AMBRX’S PROPRIETARY ANTI-PSMA ADC, ARX517, IN PROSTATE CANCER

Ambrx | February 21, 2023

Ambrx Biopharma Inc., recently released positive preliminary results from its current Phase 1 trial, APEX-01 (NCT04662580), which is examining ARX517, Ambrx's patented anti-PSMA ADC, in patients with prostate cancer. Patients with advanced prostate cancer who have progressed on at least two prior FDA-approved treatments are enrolled in the Phase 1, first-in-human, open label dose escalation and dose expansion experiment known as APEX-01. In the US, APEX-01 is the only clinic...

Read More
news image

Pharma Tech

XERIS PHARMACEUTICALS ENTERS COLLABORATION AGREEMENT WITH MERCK

Xeris | October 25, 2021

Xeris Biopharma Holdingsa biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck , with an option to license Xeris “We are quite excited to be working closely with Merck on this opportunity using our novel platform technology, XeriJect The XeriJect platform has broad applicability in improving the delivery of...

Read More
news image

Business Insights

CYCLENIUM PHARMA AND VUJA DE SCIENCES ANNOUNCE ONCOLOGY DRUG DISCOVERY COLLABORATION

Cyclenium Pharma | January 06, 2022

Cyclenium Pharma, Inc. an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, and Vuja De Sciences, Inc. a biotechnology startup dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence, have announced today the signing of a drug discovery collaboration agreement. The companies will ...

Read More
news image

Business Insights

ACURX PHARMACEUTICALS TO JOIN THE RUSSELL MICROCAP INDEX®

Acurx Pharmaceuticals, Inc. | September 06, 2021

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate gr...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us